Novavax (NVAX)
(Delayed Data from NSDQ)
$18.17 USD
-1.39 (-7.08%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $18.17 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Brokerage Reports
0 items in cart
Novavax, Inc. [NVAX]
Reports for Purchase
Showing records 221 - 240 ( 296 total )
Company: Novavax, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of August 24
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Novavax, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of August 17
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Novavax, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE: 2015 Wedbush PacGrow Healthcare Conference Day 2
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Novavax, Inc.
Industry: Medical - Biomedical and Genetics
Novavax Demonstrates Efficacy of RSV Vaccine in Elderly with Phase 3 Clarity to Come; Reiterate OUTPERFORM and Raising PT to $14.
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Novavax, Inc.
Industry: Medical - Biomedical and Genetics
New Quadrivalent Flu Vaccine Performs Against All Strains of Seasonal Influenza; Reiterate OUTPERFORM and Raising PT to $13
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Novavax, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of July 27
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Novavax, Inc.
Industry: Medical - Biomedical and Genetics
On the Road with Novavax Ahead of Transformational 3Q15; Reiterate OUTPERFORM and Raising PT to $11
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Novavax, Inc.
Industry: Medical - Biomedical and Genetics
1Q15 In Line Ahead of Data From Four Studies in 3Q15
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Novavax, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of May 4th
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Novavax, Inc.
Industry: Medical - Biomedical and Genetics
On Site with Novavax as it Prepares for a Transformational Year
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Novavax, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of April 6th
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Novavax, Inc.
Industry: Medical - Biomedical and Genetics
Additional Early Ebola Data Supportive of Novavax''s Pandemic Vaccine Platform
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Novavax, Inc.
Industry: Medical - Biomedical and Genetics
4Q14 in Line with Key Data Readouts Coming in 2H15
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Novavax, Inc.
Industry: Medical - Biomedical and Genetics
Ebola Vaccine Moves into Human Development on Heels of Positive Primate Data
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Novavax, Inc.
Industry: Medical - Biomedical and Genetics
Paving the Way to Pivotal Studies with Room for Upside
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Novavax, Inc.
Industry: Medical - Biomedical and Genetics
Paving the Way to Pivotal Studies with Room for Upside
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Novavax, Inc.
Industry: Medical - Biomedical and Genetics
Company: Novavax, Inc.
Industry: Medical - Biomedical and Genetics
Ebola Vaccine Further Validates Recombinant Vaccine Platform
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Novavax, Inc.
Industry: Medical - Biomedical and Genetics
Ebola Vaccine Further Validates Recombinant Vaccine Platform
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Novavax, Inc.
Industry: Medical - Biomedical and Genetics
Data Presentation Further Strengthens Case for RSV-F Vaccine
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H